Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.49 USD | +1.51% | -2.80% | +49.44% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 12.37M | Capitalization | 1.61B |
---|---|---|---|---|---|
Net income 2024 * | -217M | Net income 2025 * | -236M | EV / Sales 2024 * | - |
Net cash position 2024 * | 370M | Net cash position 2025 * | - | EV / Sales 2025 * | 130 x |
P/E ratio 2024 * |
-8.47
x | P/E ratio 2025 * |
-8.24
x | Employees | 142 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.5% |
Latest transcript on Kura Oncology, Inc.
1 day | +1.51% | ||
1 week | -2.80% | ||
Current month | +9.53% | ||
1 month | +9.36% | ||
3 months | +0.51% | ||
6 months | +127.65% | ||
Current year | +49.44% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
CEO | Chief Executive Officer | 55 | 14-08-21 |
Stephen Dale
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-08-24 |
Kathleen Ford
COO | Chief Operating Officer | 77 | 19-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 21-06-02 |
Faheem Hasnain
BRD | Director/Board Member | 65 | 15-04-26 |
Thomas Malley
BRD | Director/Board Member | 55 | 15-10-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 21.49 | +1.51% | 436,449 |
24-05-24 | 21.17 | -1.21% | 260,061 |
24-05-23 | 21.43 | -4.97% | 641,504 |
24-05-22 | 22.55 | +1.99% | 670,576 |
24-05-21 | 22.11 | -0.58% | 477,320 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.44% | 1.61B | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- KURA Stock